This article was downloaded by: [Colorado State University] On: 30 October 2013, At: 05:30 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information:

http://www.tandfonline.com/loi/lsyc20

General and Facial Synthesis of 2-Amino-5-halogenpyrimidine-4-carboxylic Acids and Their Derivatives

Evgeniy V. Blyumin^a, Hans Neunhoeffer^a & Yulian V. Volovenko^b ^a Darmstadt University of Technology, Institute of Organic Chemistry, Darmstadt, Germany

^b Kiev Taras Schevchenko University, Chemical Department, Kiev, Ukraine Published online: 03 Jul 2007.

To cite this article: Evgeniy V. Blyumin, Hans Neunhoeffer & Yulian V. Volovenko (2007) General and Facial Synthesis of 2-Amino-5-halogenpyrimidine-4-carboxylic Acids and Their Derivatives, Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry, 37:13, 2231-2241, DOI: <u>10.1080/00397910701396930</u>

To link to this article: http://dx.doi.org/10.1080/00397910701396930

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions

Synthetic Communications[®], 37: 2231–2241, 2007 Copyright © Taylor & Francis Group, LLC ISSN 0039-7911 print/1532-2432 online DOI: 10.1080/00397910701396930



General and Facial Synthesis of 2-Amino-5-halogenpyrimidine-4-carboxylic Acids and Their Derivatives

Evgeniy V. Blyumin and Hans Neunhoeffer

Darmstadt University of Technology, Institute of Organic Chemistry, Darmstadt, Germany

Yulian V. Volovenko

Kiev Taras Schevchenko University, Chemical Department, Kiev, Ukraine

Abstract: A facile synthetic approach to 2-amino-5-halogen-pyrimidine-4-carboxylic acids from 5-halogen-2-methylsulfonylpyrimidine-4-carboxylic acid by nucleophilic displacement of the methylsulfonyl group with primary and secondary aliphatic amines has been developed. The titled amino acids underwent decarboxylation, yielding 2-amino-5-halogenpyrimidines. Starting from 2-amino-5-chloropyrimidine-4-carboxylic acid chlorides, 2-[5-chloro-2-(amino)-4-pyrimidinyl]-2-oxo-1-(2-pyridyl)-ethyl cyanides were obtained in excellent yields.

Keywords: amino acids, aminopyrimidines, nucleophilic substitution, regioselectivity

INTRODUCTION

In the field of medicinal chemistry, substituted 2-aminopyrimidines are one of the most important structural motifs, existing within many pharmaceutically useful compounds. For example, Trimethoprim and Tetroxoprim are famous bactericides,^[1a] and Mizolastine is known as an effective histamine H1-receptor antagonist.^[1b,c] Substituted 2-amino-5-halogen-pyrimidine-4-

Received in Poland November 4, 2006

Address correspondence to Evgeniy V. Blyumin, DSM Nutritional Products Ltd., NRD/CP 205/318, P. O. Box 3255, CH-4002 Basel, Switzerland. E-mail: yevgen.blyumin@dsm.com

E. V. Blyumin, H. Neunhoeffer, and Y. V. Volovenko



Scheme 1.

carboxylic acid derivatives have been shown to possess anti-AIDS,^[2] bactericidal,^[3] antihypertensive, and antithrombozytic activity^[4] and are known as effective uridine phosphorylase and DHO DHase inhibitors.^[5,6] Furthermore, these compounds have also been used as starting materials in the synthesis of new anti-Alzheimer's pharmaceuticals^[7] and other biologically active compounds.^[3,8]

Known routes for preparing the titled compounds are limited to primary pyrimidine-ring synthesis,^[9] oxidation of the alkyl groups on the C-4(6) position,^[10] or functionalization of an NH₂-group in 2-amino-5-halogenpyrimidine-4-carboxylic acid.^[3] Therefore, only a few representatives of this class of amino acids are known. Recently, we have developed a flexible and general approach to cyanides **2** using nucleophilic displacement of the methylsulfonyl group in **1** by amines (Scheme 1).^[11–13]

In the case of the pyridine derivative, the reaction afforded condensed pyridopyrimidines **3** as the only isolable products.^[12] This fact prompted us to look for alternative approaches to compounds **4**, based on 2-amino-5-halogenpyrimidine-4-carboxylic acids **5** as starting materials. Because of the lack of a general method for the synthesis of amino acids **5**, herein we describe our results for a facile synthesis and synthetic application of these compounds.

RESULTS AND DISCUSSION

It is known that the methylsulfonyl group in the second position of the pyrimidine ring can be readily substituted by nucleophiles.^[14] Moreover, such substitution occurs easily and faster when compared to 2-chloro- and 2-(alkyl)mercaptopyrimidines, and this was successfully applied in the so-called sulfinate catalysis.^[15–17] Therefore, our approach was based on functional group manipulations of existing pyrimidine derivatives (Scheme 2). The starting 5-halogen-2-methylsulfonyl-pyrimidine-4-carboxylic acids **6a,b**



were obtained by condensation of *S*-methylisothiourea with mucochloric (or mucobromic) acid,^[18,19] followed by oxidation of the methylmercapto group^[19,20] to give **6a,b** in 75% overall yield. Treatment of **6a,b** with aliphatic amines in dimethylformamide at ambient temperature afforded the amino acids **5a–1**. Thus, the reaction occurs regioselectively with substitution of the methylsulfonyl group, yielding desired products in synthetically useful yields (Table 1). Gratifyingly, the procedure was scalable, and we were able to conduct this reaction on a 25 mmol scale, generating 4.87 g (80% isolated yield) of **5h**. In spite of their simple structures, all synthesized compounds **5a–1** are hitherto unknown representatives of 2-amino-5-halogen-pyrimidine-4-carboxylic acids.^[21]

The compounds 5a-l were fully characterized by their analytical and spectroscopic properties. Their ¹H NMR spectra revealed signals of an amine moiety along with a one-proton singlet at 8.42-8.48 ppm assigned to the proton at the C-6 position of the pyrimidine ring. The location of an amine moiety at the C-2 position of the ring was uniquely confirmed by two-dimensional NMR experiments, namely heteronuclear multiple bond correlation (HMBC) and heteronuclear single quantum correlation (HSQC). The IR spectra of compounds **5a–l** showed absorption bands at $1720-1700 \text{ cm}^{-1}$. This indicated that in the solid state amino acids 5 presumably exist in their acid and not in the betaine form. All substances 5a-l decomposed with release of a gas during meltingpoint determination. The crystals formed after cooling did not dissolve in NaHCO3 solution. Because pyrimidine-2- and 4-carboxylic acids are known to undergo thermal decarboxylation,^[14,19] we assumed that the acids 5 were undergoing a decarboxylation. This decarboxylation was also observed under heating in toluene with a catalytic amount of tripropylamine. This led to the spectroscopically pure aminopyrimidines 7a-c in almost quantitative yields (Scheme 2). Therefore the procedure described represents a new and simple synthetic method of 2-amino-5-halogenpyrimidines, which were reported to possess a variety of biological activities. [22-24]

The acids 5g,h were reacted with thionyl chloride in chloroform and afforded acid chlorides 8a,b quantitatively. When compounds 8a,b were treated with pyridine-2-yl-acetonotrile 9 in the presence of pyridine in dioxane,



Scheme 3.

Compound	NR^1R^2
5a, 7b	NH
	\bigcirc
5b	NH
5c	
	$\langle \rangle$
5d, 7b	N
5e	N
5f	
5g, 7c, 8a, 4a	N
5h, I, 8b, 4b	N
<i>c</i> :	-N-
51	\bigcirc
	O NH ₂
5j	
	(Ph
5k	N

Table 1. Substituents for compounds 4, 5, and 7*a*

^{*a*}Hal = Br for **5**l; for other compounds Hal = Cl.

the desired 2-[5-chloro-2-(amino)-4-pyrimidinyl]-2-oxo-1-(2-pyridyl)-ethyl cyanides **4a**,**b** were obtained as the only products in excellent yields (Scheme 3).

To test the generality of this approach, other 2-azahetarylacetonitriles (e.g., 1-methyl-benzimidazol-2-yl-acetonitrile and benzothiazol-2-yl-acetonitrile) were studied. In all cases, *C*-acylated derivatives of type **2** (Scheme 1) were obtained. Hence, this method represents an alternative synthetic approach toward the earlier described 2-[5-chloro-2-(amino)-4-pyrimidinyl]-2-oxo-1-(2-hetaryl)-ethyl cyanides.^[11,12]

In conclusion, our investigation has successfully provided a general and facile synthesis of substituted 2-amino-5-halogen-pyrimidine-4-carboxylic acids that is amenable to the preparation of a variety of 2-amino-pyrimidine derivatives. This study also established a new strategy for the synthesis of cyanides **2** and represents the only method available for the preparation of substituted 2-[5-chloro-2-(amino)-4-pyrimidinyl]-2-oxo-1-(2-pyridyl)-ethyl cyanides **4**. These reactions are also readily scaled, generating multigram quantities of the 2-amino-pyrimidine derivatives, compounds that can be used as synthetic building blocks and as scaffolds for combinatorial synthesis.

EXPERIMENTAL

Melting points were determined using an Electrothermal melting-point apparatus and are uncorrected. IR spectra were obtained on a Nicolet impact 400 spectrometer. ¹H and ¹³C NMR spectra were recorded on a Bruker AC-300 or Bruker Avance 500 spectrometer. MS were determined on a Varian 212 instrument at 70 eV. Elemental analyses (C, H, N) were conducted using the Perkin-Elmer CHN 240 A or 240 B.

General Procedure for Preparation of Substituted 2-Amino-5-halogen-pyrimidine-4-carboxylic acids 5a-l

To a solution of the corresponding 2-methylsulfonyl-5-halogen-pyrimidine-4carboxylic acid **6a,b** (5 mmol) in dimethylformamide (10 mL), an appropriate amine (15 mmol) was added, and the mixture was stirred at room temperature for 12 h. The solvent was then removed in vacuo (temperature of the water bath did not to exceed 70° C). The residue was dissolved in water (5– 10 mL), neutralized with 0.2 N HCl, and left overnight at 8–10°C. The precipitated crystals were collected by filtration and washed with cold water (2 mL) to give usually pure compounds. For further purification (if necessary), the acids were recrystallized from a water–ethanol (4:6) mixture.

Data

2-Benzylamino-5-chloropyrimidine-4-carboxylic acid 5a. Yield (75%). Pale yellow crystals, mp 161–162°C (dec.). ¹H NMR (500 MHz, DMSO-

d₆): δ = 8.42 (1H, s, pyrim-H), 8.26 (1H, br. s, NH), 7.40–7.20 (5H, m, Ar*H*), 4.62 (2H, d, *J* 6.26 Hz, -*CH*₂-NH). (COOH proton was not observed, probably due to exchange with water in DMSO-d₆). ¹³C NMR (125 MHz, DMSO-d₆): δ = 164.5, 159.8, 158.0, 140.9, 127.8, 127.7, 126.6, 126.2, 112.0, 43.7. IR $\nu_{\rm max}$ (KBr): 3290 (NH), 1710 (COOH) cm⁻¹. Anal. calcd. for C₁₂H₁₀ClN₃O₂: C, 54.66;H, 3.82; N, 15.94. Found: C, 54.83; H, 3.65; N, 15.80.

5-Chloro-2-(phenylethylamino)-pyrimidine-4-carboxylic acid 5b. Yield (83%). Pale yellow crystals, mp 171.5–172.5°C (dec.). ¹H NMR (300 MHz, DMSO-d₆): δ = 9.96 (1H, br. s, COOH), 8.43 (1H, s, pyrim.-H), 7.83 (1H, br. s, NH), 7.26 (5H, m, ArH), 3.46 (2H, m, CH₂CH₂-NH), 2.83 (2H, t, *J* 7.2 Hz, *CH*₂CH₂-NH). ¹³C NMR (75 MHz, DMSO-d₆): δ = 164.9, 160.1, 158.3, 157.1, 139.4, 128.7, 128.6, 126.0, 112.0, 42.5, 34.5. IR ν_{max} (KBr): 3290 (NH), 1710 (COOH) cm⁻¹. Anal. calcd. for C₁₃H₁₂ClN₃O₂: C, 56.23; H, 4.36; N, 15.13. Found: C, 56.02; H, 4.37; N, 14.98.

2-Butylamino-5-chloropyrimidine-4-carboxylic acid 5c. Yield (60%). Pale yellow crystals, mp 110–111.5°C (dec.). ¹H NMR (300 MHz, DMSO-d₆): $\delta = 9.79$ (1H, br. s, COOH), 8.44 (1H, s, pyrim.-H), 7.84 (1H, br. s, NH), 3.11 (2H, m, -CH₂CH₂-NH), 1.48 (2H, m, -CH₂CH₂), 1.27 (2H, m, -CH₂CH₃), 0.87 (3H, t, *J* 7.2 Hz, CH₃). ¹³C NMR (75 MHz, DMSO-d₆): $\delta = 165.1$, 160.2, 158.4, 156.9, 111.6, 40.5, 30.6, 19.5, 13.6. IR ν_{max} (KBr): 3280 (NH), 1710 (COOH) cm⁻¹. Anal. calcd. for C₉H₁₂ClN₃O₂: C, 47.07; H, 5.27; N, 18.30. Found: C, 47.38; H, 5.59; N, 18.28.

5-Chloro-2-diethylaminopyrimidine-4-carboxylic acid 5d. Yield (76%). Pale yellow crystals, mp 116–117°C (dec.). ¹H NMR (300 MHz, acetone-d₆): $\delta = 10.05$ (1H, br. s, COOH), 8.44 (1H, s, pyrim.-H), 3.65 (4H, q, J 7.3 Hz, *CH*₂CH₃), 1.17 (6H, t, J 7.3 Hz, *CH*₂*CH*₃). ¹³C NMR (75 MHz, acetone-d₆): $\delta = 165.1$, 158.1, 157.4, 156.5, 111.6, 40.5, 19.5. IR ν_{max} (KBr): 1710 (COOH) cm⁻¹. MS (EI): m/z (%): 229 (31) [M⁺], 214 (100), 200 (14), 183 (33), 168 (26), 154 (16), 140 (40), 128 (12), 56 (13). Anal. calcd. for C₉H₁₂CIN₃O₂: C, 47.07; H, 5.27; N, 18.30. Found: C, 47.11; H, 5.27; N, 18.34.

5-Chloro-2-dipropylamino-pyrimidine-4-carboxylic acid 5e. Yield (62%), mp 105–106.5°C (dec.). ¹H NMR (300 MHz, acetone-d₆): $\delta = 10.09$ (1H, br. s, COOH), 8.42 (1H, s, pyrim.-H), 3.57 (4H, m, *CH*₂-N-*CH*₂), 1.65 (4H, m, *CH*₂CH₃), 0.90 (6H, t, *J* 7.2 Hz, CH₂*CH*₃). IR ν_{max} (KBr): 1710 (COOH) cm⁻¹. Anal. calcd. for C₁₁H₁₆ClN₃O₂: C, 51.27; H, 6.26; N, 16.30. Found: C, 51.41; H, 6.50; N, 16.44.

5-Chloro-2-(pyrrolidin-1-yl)-pyrimidine-4-carboxylic acid **5f.** Yield (78%). Pale yellow crystals, mp 160–161°C (dec.). ¹H NMR (300 MHz, DMSO-d₆): $\delta = 13.12$ (1H, br. s, COOH), 8.47 (1H, s, pyrim.-H), 3.45 (4H, m, *CH*₂-N-*CH*₂), 1.92 (4H, m, *-CH*₂*CH*₂-). ¹³C NMR (75 MHz, DMSO-d₆):

 $\delta=165.1,\ 158.1,\ 157.6,\ 156.7,\ 111.5,\ 46.6,\ 24.9.$ IR ν_{max} (KBr): 1710 (COOH) cm $^{-1}$. Anal. calcd. for C_9H_{10}ClN_3O_2: C, 47.48; H, 4.43; N, 18.46. Found: C, 47.67; H, 4.12; N, 18.50.

5-Chloro-2-(piperidin-1-yl)-pyrimidine-4-carboxylic acid 5g. Yield (78%). Pale yellow crystals, mp 127.5–128.5°C (dec.). ¹H NMR (500 MHz, DMSO-d₆): δ = 14.10 (1H, br. s, COOH), 8.48 (1H, s, pyrim.-H), 3.71 (4H, m, *CH*₂-N-*CH*₂), 1.63 (4H, m, 2CH₂), 1.52 (2H, m, CH₂). ¹³C NMR (125 MHz, DMSO-d₆): δ = 165.0, 158.8, 158.4, 156.5, 111.6, 44.5, 25.1, 24.0. IR ν_{max} (KBr): 1710 (COOH) cm⁻¹. Anal. calcd. for C₁₀H₁₂ClN₃O₂: C, 49.70; H, 5.00; N, 17.39. Found: C, 49.79; H, 4.90; N, 17.39.

5-Chloro-2-(morpholin-4-yl)-pyrimidine-4-carboxylic acid 5h. Yield (77%). Pale yellow crystals, mp 119.5–120.5°C (dec.). ¹H NMR (300 MHz, DMSO-d₆): $\delta = 13.70$ (1H, br. s, COOH), 8.48 (1H, s, pyrim.-H), 3.67 (8H, m, morph.-H). (COOH proton was not observed, probably due to exchange with water in acetone-d₆). ¹³C NMR (75 MHz, DMSO-d₆): $\delta = 164.9$, 158.9, 158.5, 156.5, 112.7, 65.7, 43.9. IR ν_{max} (KBr): 1705 (COOH) cm⁻¹. Anal. calcd. for C₉H₁₀ClN₃O₃: C, 44.37; H, 4.14; N, 17.25. Found: C, 44.30; H, 4.26; N, 16.99.

2-(4-Carbamoylpiperidin-1-yl)-5-chloropyrimidine-4-carboxylic acid 5i. Yield (84%). Pale yellow crystals, mp 121.5–122.5°C (dec.). ¹H NMR (300 MHz, DMSO-d₆): $\delta = 13.90$ (1H, br. s, COOH), 8.45 (1H, s, pyrim. -H), 7.30 (1H, s, CONH), 6.82 (1H, s, CONH), 4.54 (1H, m, piper.-H), 2.93 (2H, m, piper.-H), 2.39 (2H, m, piper.-H), 1.80 (2H, m, piper.-H), 1.44 (2H, m, piper.-H). ¹³C NMR (75 MHz, DMSO-d₆): $\delta = 175.9$, 165.0, 158.8, 158. 5, 156.6, 111.9, 44.3, 41.4, 27.9. IR ν_{max} (KBr): 1715 (COOH) cm⁻¹. Anal. calcd. for C₁₁H₁₃ClN₄O₃: C, 46.41; H, 4.60; N, 19.68. Found: C, 46.59; H, 4.76; N, 19.70.

5-Chloro-2-(4-benzylpiperidin-1-yl)-pyrimidine-4-carboxylic acid 5j. Yield (54%). Pale yellow crystals, mp 111–112°C (dec.). ¹H NMR (100 MHz, acetone-d₆): $\delta = 8.43$ (1H, s, pyrim.-H), 7.34–7.1 (5H, m, ArH), 5.20 (2H, m, CH₂Ph), 4.63 (2H, m, piper.-H), 2.90 (2H, m, piper.-H), 2.56 (2H, m, piper.-H), 1.77 (2H, m, piper.-H), 1.27 (1H, m, piper.-H), 2.56 (2H, m, piper.-H), 1.77 (2H, m, piper.-H), 1.27 (1H, m, piper.-H). (COOH proton was not observed, probably due to exchange with water in acetone-d₆). IR ν_{max} (KBr): 1720 (COOH) cm⁻¹. Anal. calcd. for C₁₇H₁₈ClN₃O₂: C, 61.54; H, 5.47; N, 12.66. Found: C, 61.55; H, 5.21; N, 12.72.

2-(1-Azepanyl)-5-chloropyrimidine-4-carboxylic acid 5k. Yield (64%). Pale yellow crystals, mp 133.5–134.5°C (dec.). ¹H NMR (100 MHz, acetone-d₆): $\delta = 8.44$ (1H, s, pyrim.-H), 3.85–3.7 (4H, m, *CH*₂-N-*CH*₂), 1.90–1.45 (8H, m, -(*CH*₂)₄-). (COOH proton was not observed, probably due to exchange with water in acetone-d₆). IR ν_{max} (KBr): 1715 (COOH) cm⁻¹. Anal. calcd. for C₁₁H₁₄ClN₃O₂: C, 51.67; H, 5.52; N, 16.43. Found: C, 51.54; H, 5.41; N, 16.12.

5-Bromo-2-(morpholin-4-yl)-pyrimidine-4-carboxylic acid 51. Yield (76%). Pale yellow crystals, mp 131.5–132.5°C (dec.). ¹H NMR (100 MHz, acetone-d₆): $\delta = 8.56$ (1H, s, pyrim.-H), 3.74 (8H, m, morph.-H). (COOH proton was not observed, probably due to exchange with water in acetone-d₆). ¹³C NMR (75 MHz, DMSO-d₆): $\delta = 164.9$, 158.9, 158.5, 156.5, 112.7, 65.7, 43.9. IR ν_{max} (KBr): 1705 (COOH) cm⁻¹. Anal. calcd. for C₉H₁₀BrN₃O₃: C, 37.52; H, 3.50; N, 14.59. Found.: C, 37.39; H, 3.34; N, 14.55.

Decarboxylation of Acids 6: General Procedure for Preparation of 2-Amino-5-chloropyrimidines 7a-c

To solution of corresponding 2-amino-5-chloro-pyrimidine-4-carboxylic acid **5** (2 mmol) in toluene (10 mL), tripropylamin (0.1 mL) was added. The mixture was refluxed for 30 min. After solvent evaporation, the product was obtained as a yellowish solid, which as shown by NMR and TLC, does not require further purification.

Data

Benzylamino-5-chloropyrimidine 7a. Yield (99%), mp 109°C. ¹H NMR (300 MHz, DMSO-d₆): $\delta = 8.36$ (2H, s, pyrim.-H), 7.41-7.23 (5H, m, Ar*H*), 6.70 (1H, d, *J* 6.2 Hz, NH), 4.62 (2H, d, *J* 6.2 Hz, -*CH*₂-NH). Anal. calcd. for C₁₁H₁₀ClN₃: C, 60.14; H, 4.59; N, 19.13. Found: C, 60.27; H, 4.55; N, 18.97.

5-Chloro-2-diethylaminopyrimidine 7b. Yield (99%). Yellowish crystals, mp 86°C. ¹H NMR (300 MHz, DMSO-d₆): $\delta = 8.37$ (2H, s, pyrim.-H), 3.65 (4H, q, *J* 7.3 Hz, *CH*₂CH₃), 1.17 (6H, t, *J* 7.3 Hz, CH₂CH₃). Anal. calcd. for C₈H₁₂ClN₃: C, 51.76; H, 6.52; N, 22.63. Found: C, 51.85; H, 6.79; N, 22.69.

5-Chloro-2-(piperidin-1-yl)-pyrimidine 7c. Yield (99%). Yellowish crystals, mp 96°C. ¹H NMR (500 MHz, DMSO-d₆): $\delta = 8.36$ (2H, s, pyrim.-H), 3.70 (4H, m, *CH*₂-N-*CH*₂), 1.63–1.49 [6H, 2 m, -(*CH*₂)₃-). ¹³C NMR (125 MHz, DMSO-d₆): $\delta = 159.8$, 156.2, 117.0, 44.8, 25.5, 24.5. MS (EI) m/z (%): 197 (M⁺) (100), 182 (49), 168 (73), 154 (44), 142 (25), 114 (32), 84 (19). Anal. calcd. for C₈H₁₂ ClN₃: C, 54.69; H, 6.12; N, 21.26. Found: C, 54.75; H, 6.12; N, 21.41.

5-Chloro-2-(piperidin-1-yl)-pyrimidine-4-carboxylic acid chloride 8a. To a suspension of 5-chloro-2-(piperidin-1-yl)-pyrimidine-4-carboxylic acid

(5g) (2.41 g, 10 mmol) in benzene (20 mL), thionylchloride (2.38 g, 20 mmol) was added, and the mixture was refluxed for 2 h. After solvent evaporation, the product was obtained as a yellow solid, which was used in further transformations without purification. Yield 2.57 g (99%), mp 94–95°C. ¹H NMR (100 MHz, CDCl₃): $\delta = 8.42$ (1H, s, pyrim.-H), 3.87–3.73 (4H, m, *CH*₂-N-*CH*₂), 1.75–1.45 [6H, m, -(*CH*₂)₃-].

5-Chloro-2-(morpholin-4-yl)-pyrimidine-4-carboxylic acid chloride 8b. According to the procedure for **8a**, compound **8b** was obtained as a yellow solid. Yield (100%), mp 97–98°C. ¹H NMR (100 MHz, CDCl₃): $\delta = 8.43$ (1H, s, pyrim.-H), 3.80 (8H, m, morph.-H).

2-[5-Chloro-2-(piperidin-1-yl)-pyrimidin-4-yl]-2-oxo-1-(pyridin-2-yl)-propio-nitrile 4a. To a solution of pyridin-2-yl-acetonitrile **9** (240 mg, 2 mmol) and pyridine (2.2 mmol, 0.180 mL) in anhydrous dioxane (20 mL), **8a** (0.52 g, 2 mmol) was added. The reaction mixture was heated to 80–90°C for 1.5 h. After cooling, the solvent was removed in vacuo, and the residue was treated with water, filtered, dried, and recrystallized from dioxane to yield 0.65 g (95%) of **4a** as a yellow solid, mp 232–233°C. ¹H NMR (100 MHz, DMSO-d₆): δ = 15.4 (1H, br. s, chelat.-H), 8.52 (1H, s, pyrim.-H), 8.49 (1H, br. t, α -pyridine-H), 8.25 (1H, ddd, *J* 8.8, 7.4, 1.5 Hz, γ -pyridine-H), 7.46 (1H, d, *J* 8.8 Hz, pyridine-H), 7.43 (1H, dd, *J* 7.4, 5.6 Hz, pyridine-H), 3.77-3.69 (4H, m, *CH*₂-N-*CH*₂), 1.75–1.45 [6H, m, -(*CH*₂)₃-]. IR ν_{max} (KBr): 2195 (CN) cm⁻¹. Anal. calcd. for C₁₇H₁₆ClN₅O: C, 59.74; H, 4.72; N, 20.49. Found: C, 59.71; H, 4.97; N, 20.61.

2-[5-Chloro-2-(morpholin-4-yl)-pyrimidin-4-yl]-2-oxo-1-(pyridin-2-yl)propio-nitrile 4b. According to the procedure for **4a**, compound **4b** was obtained as a yellow solid. Yield (84%), mp 247–248°C. ¹H NMR (100 MHz, DMSO-d₆): $\delta = 15.40$ (1H, br. s, chelat.-H), 8.53 (1H, s, pyrim. -H), 8.49 (1H, br. t, α -pyridine-H), 8.25 (1H, ddd, J 8.8, 7.4, 1.5 Hz, γ -pyridine-H), 7.46 (1H, d, J 8.8 Hz, pyridine-H), 7.43 (1H, dd, J 7.4, 5. 6 Hz, pyridine-H), 3.69 (8H, m, morph.-CH₂). IR ν_{max} (KBr): 2195 (CN) cm⁻¹. MS (EI) m/z (%): 343 (M⁺) (98), 308 (100), 285 (76), 250 (16), 197 (14), 145 (55), 117 (21), 90 (16). Anal. calcd. for C₁₆H₁₄ClN₅O₂: C, 55.90; H, 4.10; N, 20.37. Found: C, 55.93; H, 4.15; N, 20.21.

REFERENCES

(a) Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D. *Pharmaceutical Substances*; Thieme: Stuttgart, 2001, pp. 2004, 2115; (b) Danjou, E. P.; Molinier, P.; Berlin, I.; Patat, A.; Rosenzweig, P.; Morselli, P. L. Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects. Brit. J. Clin. Pharmacol. **1992**, *34* (4), 328–331; (c) Rosenzweig, P.; Thebault, J. J.; Caplain, H.; Dubruc, C.; Bianchetti, G.; Fuseau, E.; Morselli, P. L. *Annals Allergy* **1992**, *69* (2), 135–139.

- Kukla, M. J.; Ludovici, D. W.; Kavash, R. W.; De Corte, B. L. D.; Heeres, J.; Janssen, P. A. J.; Koymans, L. M. H.; De Jonge, M. R.; Van Aken Koen, J. A.; Krief, A.; Leenders, R. G. G. Preparation of substituted amino pyrimidines and triazines as HIV replication inhibitors. WO, 0185700, 2001; *Chem. Abstr.* 2001, *135*, 371765.
- Lubisch, W.; Moeller, A.; Treiber, H.-J.; Knopp, M. New substituted heterocyclic amides, their preparation and application. DE, 19817459, 1999; *Chem. Abstr.* 1999, 131, 299438.
- Narr, B.; Roch, J.; Mueller, E.; Haarmann, W. Pyrimidine derivatives. DE, 2341925, 1975; Chem. Abstr. 1975, 83, 43369.
- Jimenez, B. M.; Kranz, P.; Lee, C. S.; Gero, A. M.; O'Sullivan, W. J. Inhibition of uridine phosphorylase from *Giardia lamblia* by pyrimidine analogs. *Biochem. Pharmacol.* **1989**, *38*, 3785; *Chem. Abstr.* **1990**, *112*, 195107.
- Gero, A. M.; O'Sullivan, W. J.; Brown, D. Human spleen dihydroorotate dehydrogenase: A study of inhibition of the enzyme. *Biochem. Med.* 1985, *34*, 60; *Chem. Abstr.* 1985, *103*, 156291.
- Dunbar, P. G.; Durant, G. J.; Rho, T.; Ojo, B. Huzl, J. J. III.; Smith, D. A.; El-Assadi, A. A.; Sbeih, S.; Ngur, D. O.; Periyasamy, S.; Hoss, W.; Messer, W. S. Jr. Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines and 2-amino-5-(alkoxycarbonyl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. *J. Med. Chem.* 1994, *37*, 2774.
- Muzi, S.; Abdul-Rahman, S. Novel compounds, specifically aromatic and heteroaromatic ureas and thioureas, useful against parasites and especially against coccidiosis. WO, 0130749, 2001; *Chem. Abstr.* 2001, *134*, 340357.
- Jart, A. Infrared spectra of carboxylic acid derivatives. I. S-Benzylthiouronium salts. II. p-Bromophenacyl esters. *Acta Polytech. Scand. Chem. Metall. Ser.* 1963, 24, 120.
- Bray, H. G.; Thorpe, W. V.; Wood, P. B. Fate of certain organic acids and amides in the rabbit, XII: Aminohydroxybenzoic acids. *Biochem. J.* 1951, 48, 394–399.
- Volovenko, Y. M.; Blyumin, E. V. Nucleophilic substitution in a series of 2-methylsulfonyl-5-chloropyrimidine-4-carboxylic acid derivatives. *Chem. Het*erocycl. Compd. (NY) 1998, 34, 324–328.
- Volovenko, Y. M.; Blyumin, E. V. Nucleophilic substitution in some 5-chloropyrimidines: Synthesis and properties of condensed pyridopyrimidines. *Tetrahedron* 2000, 56, 5185.
- Volovenko, Y. M.; Blyumin, E. V.; Volovnenko, T. A.; Shokol, T. V.; Shishkin, O. V. 2-(3,4-Dihydro-4-oxo-2-quinazolinyl)acetonitriles in the synthesis of new condensed pyrimidines. *Synthesis* 2004, *16*, 2659–2664.
- Brown, D. J. The Pyrimidines. In *Chemistry Heterocylic Compounds*; Wiley: New York, 1994.
- Bessard, Y.; Stucky, G. Process for the preparation of substituted pyrimidines, EP, 802,193, 1997; Chem. Abstr. 1997, 127, 358872.
- Miyashita, A.; Suzuki, Y.; Otha, K.; Higashino, T. Preparation of heteroarenecarbonitriles by reaction of haloheteroarenes with potassium cyanide with sodium p-toluenesulfinate as catalyst. *Heterocycles* 1994, *39*, 345–356.
- Bessard, Y.; Crettaz, R. Rate acceleration of nucleophylic substitution of 2-chloro-4,6-dimethoxypyrimidine by sulfinate catalysis. *Tetrahedron* 2000, 56, 4739–4745.
- (a) Grant, G. A.; Seemann, C. V.; Winthrop, S. O. Basic esters of substituted pyrimidine-4-carboxylic acids. *Can. J. Chem.* 1956, 34, 1444–1446;

(b) McOmie, J. F. W.; White, I. M. Pyrimidines: VI: 5-Bromopyrimidine. J. Chem. Soc. **1953**, 3129–3131.

- Liang, Y. M.; Luo, S. J.; Zhang, Z. X.; Ma, Y. X. Efficient synthesis of a new pyrimidine derivative. *Synth. Commun.* 2002, 1, 153–158.
- Budesinsky, Z.; Vavrina, J.; Langsadl, L.; Holubek, J. On the synthesis of 4- and 5-pyrimidinyldiphenyl-(1-imidazolyl)methanes and their antifungal activity. *Collect. Czech. Chem. Commun.* 1980, 45, 539–547.
- The possibility of the synthesis of type 5 compounds (by the example of 5b, 5f, 5h) from 6a has been outlined in Blyumin, E. V.; Volovenko, Y. M. Reactions of 5-chloro-2-methylsulfonyl-4-pyrimidinecarboxylic acid and its esters with amines: The inversion of reactivity in a pyrimidine ring. *Mendeleev. Commun.* 2000, *6*, 237–238.
- Fliri, A. F. J.; Sanner, M. A.; Seymour, P. A.; Zorn, S. H. Dopamine D4 ligands for the treatment of novelty-seeking disorders. EP, 1177792, 2002; *Chem. Abstr.* 2002, *136*, 145264.
- Tabuchi, T.; Yamamoto, T.; Nakayama, M. Preparation of aryl- or heterocyclylsulfonamide derivatives as agricultural and horticultural microbicides. WO, 0065913, 2000; *Chem. Abstr.* 2000, 133, 350233.
- Beight, D. W.; Craft, T. J.; Denny, C. P.; Franciskovich, J. B.; Goodson, T., Jr.; Hall, S. E.; Herron, D. K.; Joseph, S. P.; Klimkowski, V. J.; Masters, J. J.; Mendel, D.; Milot, G.; Pineiro-Nunez, M. M.; Sawyer, J. S.; Shuman, R. T.; Smith, G. F.; Tebbe, A. L.; Tinsley, J. M.; Weir, L. C.; Wikel, J. H.; Wiley, M. R.; Yee, Y. K. Preparation of heteroaryl-substituted aromatic amides as factor Xa inhibitors. WO, 0039118, 2000; *Chem. Abstr.* 2000, *133*, 89437.